| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
No pharmacological target. The compound is a surface-modification reagent for lipid-based delivery systems. Its functional “target” is the amine group of a targeting ligand (via carbodiimide-mediated coupling) and the lipid bilayer of the nanoparticle.
|
|---|---|
| ln Vitro |
No intrinsic pharmacological activity. Its performance is defined by carboxyl reactivity (coupling efficiency to amine ligands), PEG surface density, and the resulting nanoparticle’s circulation half-life and targeting specificity. No IC50 or EC50 values are applicable.
|
| ln Vivo |
In vivo, DSPE-PEG-Carboxylic Acid-containing nanoparticles show prolonged circulation and reduced clearance by the reticuloendothelial system. When conjugated to a targeting ligand, they enhance accumulation in target tissues (e.g., tumors). Efficacy depends on the delivered cargo and targeting strategy.
|
| Enzyme Assay |
In vitro characterization involves formulation of liposomes or LNPs with the compound and measurement of particle size, zeta potential, and PEG surface density. Carboxyl activation (e.g., with EDC/NHS) and coupling to a model amine ligand are assessed by NMR, HPLC, or a colorimetric amine assay.
|
| Cell Assay |
In vitro cell-based assays evaluate cellular uptake of nanoparticles containing DSPE-PEG-Carboxylic Acid, with or without a conjugated targeting ligand. Cells are incubated with fluorescently labeled nanoparticles, and uptake is quantified by flow cytometry or fluorescence microscopy. Cytotoxicity is measured by MTT or LDH release.
|
| Animal Protocol |
In vivo animal experiments use nanoparticles containing DSPE-PEG-Carboxylic Acid administered intravenously to rodents. Biodistribution is assessed by imaging or tissue analysis of a labeled cargo, and targeting efficacy is compared between ligand-conjugated and unconjugated formulations. Tolerability is monitored by body weight and histopathology.
|
| References |
| Molecular Formula |
C46H91N2O13P
|
|---|---|
| Molecular Weight |
911.194116830826
|
| Exact Mass |
910.625
|
| CAS # |
474922-20-8
|
| Related CAS # |
474922-20-8
|
| PubChem CID |
156591922
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
194
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
62
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)OCCOCC(=O)O)OC(=O)CCCCCCCCCCCCCCCCC.N
|
| InChi Key |
MFOLYTNLQCGGBD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C46H88NO13P.H3N/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-44(50)57-39-42(40-59-61(53,54)58-36-35-47-46(52)56-38-37-55-41-43(48)49)60-45(51)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h42H,3-41H2,1-2H3,(H,47,52)(H,48,49)(H,53,54);1H3
|
| Chemical Name |
azane;2-[2-[2-[2,3-di(octadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethylcarbamoyloxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0975 mL | 5.4873 mL | 10.9747 mL | |
| 5 mM | 0.2195 mL | 1.0975 mL | 2.1949 mL | |
| 10 mM | 0.1097 mL | 0.5487 mL | 1.0975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.